Preferred Label : tildrakizumab;

MeSH hyponym : SCH-900222;

UNII : DEW6X41BEK;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3539132/fr/ilumetri-tildrakizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
injections, subcutaneous
chronic disease
tildrakizumab

---
https://www.has-sante.fr/jcms/p_3434489/fr/ilumetri-tildrakizumab-psoriasis-en-plaques
2023
false
false
false
France
evaluation of the transparency committee
tildrakizumab
psoriasis

---
https://www.has-sante.fr/jcms/p_3358137/fr/ilumetri-tildrakizumab-psoriasis-en-plaques-modere-a-severe
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
tildrakizumab
Product containing only tildrakizumab in parenteral dose form (medicinal product form)
evaluation of the transparency committee
tildrakizumab
psoriasis

---
https://www.has-sante.fr/jcms/p_3190309/fr/ilumetri
2020
false
false
false
France
tildrakizumab
tildrakizumab
tildrakizumab
treatment outcome
insurance, health, reimbursement
adult
chronic disease
psoriasis
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal

---
https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tildrakizumab
treatment outcome
drug approval
europe
adult
psoriasis
injections, subcutaneous
Interleukin-23
product surveillance, postmarketing
pregnancy
breast feeding
drug interactions
aged
drug storage
drug evaluation, preclinical
tildrakizumab
tildrakizumab
antibodies, monoclonal
antibodies, monoclonal

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.